Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GERN | GERON CORP | 2025-10-16 18:59:06 | 1.24 | 0.01 | 0.81 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GERN | 0000886744 | GERON CORP | US3741631036 | 549300T282D7Z2YESL90 | 752287752 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 919 EAST HILLSDALE BOULEVARD | FOSTER CITY | CA | 94404 | UNITED STATES | US | 6504737700 | 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404 | 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404 | GERON CORPORATION | Biotechnology | 1990 | John Scarlett | 82 | http://www.geron.com/ | 2,430,700,000 | 606,387,666 | 638,017,073 | Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase. | 2025-10-10 21:21:19 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 2,430,700,000 | 1,036,154,000 | 74.3005 | 636,904,470 | 90,845,161 | 16.6365 |
| 2023 | 1,394,546,000 | 891,359,000 | 177.1427 | 546,059,309 | 37,336,823 | 7.3393 |
| 2022 | 503,187,000 | 126,487,000 | 33.5776 | 508,722,486 | 184,990,895 | 57.1433 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Joseph Eid, M.D. | Executive Vice President | 2024 | 93,750 | 200,000 | — | 0 | 10,348 | 7,762,848 |
| Andrew J. Grethlein, Ph.D. | Chief Operating Officer, Executive Vice President | 2024 | 600 | 0 | — | 364,500 | 12,976 | 2,813,956 |
| John A. Scarlett | Chief Executive Officer, President, Chairman Of The Board | 2024 | 810,600 | 0 | — | 658,600 | 64,838 | 6,125,238 |
| Michelle J. Robertson | Chief Financial Officer, Treasurer, Executive Vice President | 2024 | 540,800 | 0 | — | 292,000 | 13,576 | 2,147,216 |
| James Ziegler | Chief Commercial Officer, Executive Vice President | 2024 | 163,221 | 0 | — | 88,300 | 1,044 | 5,768,744 |
| Fiscal Year | Employee Count |
|---|---|
| 2016 | 15 |
| 2015 | 17 |
| 2014 | 42 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 76,495,000 | 237,000 | 596,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 103,738,000 | 125,046,000 | 95,518,000 |
| General And Administrative Expenses | 145,732,000 | 69,135,000 | 43,628,000 |
| Operating Expenses | 250,726,000 | 194,181,000 | 139,146,000 |
| Operating Income | -173,732,000 | -193,944,000 | -138,550,000 |
| Net Income | -174,572,000 | -184,127,000 | -141,901,000 |
| Earnings Per Share Basic | -0.27 | -0.32 | -0.37 |
| Earnings Per Share Diluted | -0.27 | -0.32 | -0.37 |
| Weighted Average Shares Outstanding Basic | 646,033,247 | 570,645,405 | 380,784,846 |
| Weighted Average Shares Outstanding Diluted | 646,033,247 | 570,645,405 | 380,784,846 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 79,016,000 | 70,023,000 | 56,845,000 |
| Marketable Securities Current | 327,550,000 | 263,676,000 | 115,901,000 |
| Accounts Receivable | 35,946,000 | — | — |
| Inventories | 38,714,000 | — | — |
| Non Trade Receivables | 2,853,000 | 1,655,000 | 3,144,000 |
| Other Assets Current | — | — | — |
| Total Assets Current | 490,992,000 | 341,348,000 | 180,246,000 |
| Marketable Securities Non Current | 94,519,000 | 43,298,000 | — |
| Property Plant And Equipment | 1,310,000 | 1,177,000 | 793,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 102,789,000 | 52,728,000 | 10,329,000 |
| Total Assets | 593,781,000 | 394,076,000 | 190,575,000 |
| Accounts Payable | 8,595,000 | 6,161,000 | 10,190,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 2,186,000 | 46,893,000 | 20,945,000 |
| Other Liabilities Current | 35,549,000 | 40,308,000 | 33,100,000 |
| Total Liabilities Current | 88,298,000 | 108,070,000 | 76,694,000 |
| Long Term Debt | 118,476,000 | 35,051,000 | 30,212,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 225,163,000 | 38,057,000 | 33,883,000 |
| Total Liabilities | 313,461,000 | 146,127,000 | 110,577,000 |
| Common Stock | 606,000 | 545,000 | 390,000 |
| Retained Earnings | -1,772,341,000 | -1,597,769,000 | -1,413,642,000 |
| Accumulated Other Comprehensive Income | 261,000 | 185,000 | -219,000 |
| Total Shareholders Equity | 280,320,000 | 247,949,000 | 79,998,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 546,000 | 442,000 | 288,000 |
| Share Based Compensation Expense | 31,185,000 | 18,526,000 | 8,001,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 35,695,000 | — | — |
| Change In Inventories | 37,971,000 | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,435,000 | -4,029,000 | 3,503,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -218,618,000 | -167,743,000 | -127,379,000 |
| Purchases Of Marketable Securities | 476,932,000 | 475,594,000 | 258,007,000 |
| Sales Of Marketable Securities | 371,608,000 | 296,102,000 | 320,505,000 |
| Acquisition Of Property Plant And Equipment | 680,000 | 830,000 | 431,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -106,004,000 | -180,322,000 | 62,067,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 121,120,000 | 29,700,000 | — |
| Repayment Of Long Term Debt | 86,554,000 | — | — |
| Other Financing Activities | 32,683,000 | 13,072,000 | 2,185,000 |
| Cash From Financing Activities | 334,372,000 | 362,021,000 | 87,264,000 |
| Change In Cash | 9,738,000 | 13,929,000 | 21,952,000 |
| Cash At End Of Period | 79,016,000 | 70,023,000 | 56,845,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 10,364,000 | -7,017,000 | 5,154,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.27 | -0.32 | -0.37 |
| Price To Earnings Ratio | -13.1111 | -6.5938 | -6.5405 |
| Earnings Growth Rate | -15.625 | -13.5135 | — |
| Price Earnings To Growth Ratio | 0.8391 | 0.4879 | — |
| Book Value Per Share | 0.4339 | 0.4345 | 0.2101 |
| Price To Book Ratio | 8.1584 | 4.8561 | 11.519 |
| Ebitda | -155,522,000 | -175,373,000 | -134,731,000 |
| Enterprise Value | 2,328,603,694.38 | 1,215,982,804.55 | 915,811,327.32 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.4304 | 0.3305 | 0.6395 |
| Capital Expenditures | 679,000 | 826,000 | 431,000 |
| Free Cash Flow | -219,297,000 | -168,569,000 | -127,810,000 |
| Return On Equity | -0.6228 | -0.7426 | -1.7738 |
| One Year Beta | 0.6129 | 1.4491 | 1.3173 |
| Three Year Beta | 1.2051 | 1.2135 | 0.8965 |
| Five Year Beta | 0.9171 | 0.9765 | 0.9477 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Spiegel Robert J. | Director | 2025-09-30 | 5,702 | A | 188,546 |
| Semerjian Harout | Director, President and CEO | 2025-08-07 | 7,000,000 | A | 7,000,000 |
| Semerjian Harout | Director, President and CEO | 2025-08-07 | 4,000,000 | A | 4,000,000 |
| Spiegel Robert J. | Director | 2025-06-30 | 5,540 | A | 182,844 |
| Spiegel Robert J. | Director | 2025-05-21 | 180,000 | A | 180,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| CWM, LLC | 2025-09-30 | 4,000 | 3,049 | 1.3119 |
| Inspire Investing, LLC | 2025-09-30 | 450,800 | 329,051 | 1.37 |
| World Investment Advisors | 2025-09-30 | 1,424,498 | 1,039,779 | 1.37 |
| Farther Finance Advisors, LLC | 2025-09-30 | 9,880 | 7,212 | 1.3699 |
| BARTLETT & CO. WEALTH MANAGEMENT LLC | 2025-09-30 | 1,370 | 1,000 | 1.37 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| ETFis Series Trust I | 2025-07-31 | Virtus LifeSci Biotech Products ETF | BBP | 284,868 | 327,598.2 | 1.3292 |
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 2,682 | 3,084.3 | 0.0013 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 265,692 | 305,545.8 | 0.0129 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 310,616 | 357,208.4 | 0.0272 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Total Market Index Fund | FZROX | 272,720 | 313,628 | 0.0011 |